Item request has been placed!
×
Item request cannot be made.
×

Processing Request
Combining antimiR-25 and cGAMP Nanocomplexes Enhances Immune Responses via M2 Macrophage Reprogramming.
Item request has been placed!
×
Item request cannot be made.
×

Processing Request
- Author(s): Petrovic, Marija1 (AUTHOR) ; Majchrzak, Oliwia B.1 (AUTHOR) ; Marecar, Rihana Amreen Mohamed Hachime1 (AUTHOR) ; Laingoniaina, Annick C.1 (AUTHOR); Walker, Paul R.2 (AUTHOR) ; Borchard, Gerrit1 (AUTHOR); Jordan, Olivier1 (AUTHOR); Tankov, Stoyan2 (AUTHOR)
- Source:
International Journal of Molecular Sciences. Dec2024, Vol. 25 Issue 23, p12787. 18p.
- Subject Terms:
- Additional Information
- Abstract:
Glioblastoma (GBM) is an aggressive brain cancer with a highly immunosuppressive tumor microenvironment (TME), invariably infiltrated by tumor-associated macrophages (TAMs). These TAMs resemble M2 macrophages, which promote tumor growth and suppress immune responses. GBM cells secrete extracellular vesicles (EVs) containing microRNA-25, which inhibits the cGAS-STING pathway and prevents TAMs from adopting a pro-inflammatory M1 phenotype. This study characterizes antimiR-25/cGAMP nanocomplexes (NCs) for potential therapeutic applications. A particle size analysis revealed a significant reduction upon complexation with antimiR-25, resulting in smaller, more stable nanoparticles. Stability tests across pH levels (4–6) and temperatures (25–37 °C) demonstrated their resilience in various biological environments. Biological assays showed that antimiR-25 NCs interacted strongly with transferrin (Tf), suggesting potential for blood–brain barrier passage. The use of cGAMP NCs activated the cGAS-STING pathway in macrophages, leading to increased type I IFN (IFN-β) production and promoting a shift from the M2 to M1 phenotype. The combined use of cGAMP and antimiR-25 NCs also increased the expression of markers involved in M1 polarization. These findings offer insights into optimizing antimiR-25/cGAMP NCs for enhancing immune responses in GBM. [ABSTRACT FROM AUTHOR]
No Comments.